MRSN — Mersana Therapeutics Share Price
0.000.00%
Last trade - 00:00- $462.16m
- $278.51m
- $36.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 12.52 | ||
| Price to Tang. Book | 12.52 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.54 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -110.62% | ||
| Return on Equity | -266.24% | ||
| Operating Margin | -487.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 42.12 | 0.83 | 0.04 | 26.58 | 36.85 | 39.06 | 31.96 | 28.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Directors
- David Mott NEC (55)
- Anna Protopapas PRE (56)
- Brian Deschuytner SVF (43)
- Mohan Bala SVP
- Alejandra Carvajal SVP (47)
- Tushar Misra SVP
- Timothy Lowinger CTO (57)
- Arvin Yang OTH (45)
- Lawrence Alleva IND (71)
- Willard Dere IND (67)
- Allene Diaz IND (57)
- Andrew Hack IND (48)
- Kristen Hege IND (58)
- Martin Huber IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 4th, 2001
- Public Since
- June 28th, 2017
- No. of Shareholders
- 14
- No. of Employees
- 123
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 121,303,007
- Address
- 840 Memorial Dr, CAMBRIDGE, 02139-3789
- Web
- https://www.mersana.com/
- Phone
- +1 6174980020
- Auditors
- Ernst & Young LLP
Upcoming Events for MRSN
Mersana Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Mersana Therapeutics Inc Earnings Release
Similar to MRSN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Mersana Therapeutics share price?
As of Today at 19:14 UTC, shares in Mersana Therapeutics are trading at $3.81. This share price information is delayed by 15 minutes.
How has the Mersana Therapeutics share price performed this year?
Shares in Mersana Therapeutics last closed at $3.81 and the price had moved by -12.41% over the past 365 days. In terms of relative price strength the Mersana Therapeutics share price has underperformed the S&P500 Index by -29.27% over the past year.
What are the analyst and broker recommendations for Mersana Therapeutics?
The overall consensus recommendation for Mersana Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mersana Therapeutics dividend yield?
Mersana Therapeutics does not currently pay a dividend.
Does Mersana Therapeutics pay a dividend?
Mersana Therapeutics does not currently pay a dividend.
When does Mersana Therapeutics next pay dividends?
Mersana Therapeutics does not currently pay a dividend.
How do I buy Mersana Therapeutics shares?
To buy shares in Mersana Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mersana Therapeutics?
As of the previous close price of $3.81, shares in Mersana Therapeutics had a market capitalisation of $462.16m.
Where are Mersana Therapeutics shares listed?
Here are the trading details for Mersana Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MRSN
What kind of share is Mersana Therapeutics?
Based on an overall assessment of its quality, value and momentum Mersana Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mersana Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Mersana Therapeutics is $6.71. That is 76.12% above the last closing price of $3.81.
Analysts covering Mersana Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.67 for the next financial year.
What is the trend in the Mersana Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mersana Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +109.83%.
As of the last closing price of $3.81, shares in Mersana Therapeutics were trading +48.04% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mersana Therapeutics PE Ratio?
The Mersana Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mersana Therapeutics?
Mersana Therapeutics' management team is headed by:
- David Mott - NEC
- Anna Protopapas - PRE
- Brian Deschuytner - SVF
- Mohan Bala - SVP
- Alejandra Carvajal - SVP
- Tushar Misra - SVP
- Timothy Lowinger - CTO
- Arvin Yang - OTH
- Lawrence Alleva - IND
- Willard Dere - IND
- Allene Diaz - IND
- Andrew Hack - IND
- Kristen Hege - IND
- Martin Huber - IND